Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals

ECONOMISTS have vigorously debated whether advertising and other messages supplied by sellers to buyers represent the efficient provision of information or the exploitation of buyers' imperfect access to it. Many economists now agree that each view commands some truth. Advertising should convey information efficiently where the buyer can easily verify it. But it may engender inefficient rent-seeking outlays by producers able to hamper buyers' gaining of information from alternative sources. For example, if buyers sample product information randomly, an incumbent can "jam" the channels through which entrants transmit their messages by loading the sampled population with messages of his own. Or the incumbent's messages can reinforce buyers' habits so as to reduce their prior expectations of the value of trying an alternative brand.2 If sales promotion is effective (by whatever means) in causing buyers to shift among competing products, it becomes a form of rent-seeking outlay by which sellers bid for the available customers.3 The problem for empirical research is to determine the extent to which seller-supplied information pursues a rent-seeking goal and thus incurs social costs. Those costs must be set against the efficiency advantage of sellers (relative to buyers or

[1]  M. Stolar National survey of hospital pharmaceutical services--1985. , 1983, American journal of hospital pharmacy.

[2]  Martin Neil Baily,et al.  Research and Development Costs and Returns: The U.S. Pharmaceutical Industry , 1972, Journal of Political Economy.

[3]  K. Leffler,et al.  Persuasion or Information? The Economics of Prescription Drug Advertising , 1981, The Journal of Law and Economics.

[4]  A. J. Swartz Drug product selection. , 1977, American journal of hospital pharmacy.

[5]  W. S. Comanor,et al.  The political economy of the pharmaceutical industry. , 1986, Journal of economic literature.

[6]  Randall S. Brown,et al.  Estimating Advantages to Large-Scale Advertising , 1978 .

[7]  R. Caves INFORMATION STRUCTURES OF PRODUCT MARKETS , 1986 .

[8]  D Schwartzman "Innovation in the Pharmaceutical Industry". , 1978, British medical journal.

[9]  D. Gaskins,et al.  Dynamic limit pricing: Optimal pricing under threat of entry , 1971 .

[10]  R. Steiner,et al.  Generic Substitution and Prescription Prices: Economic Effects of State Drug Product Selection Laws , 1985 .

[11]  R. N. Spivey,et al.  Effect of the Drug Price Competition Act on Market Exclusivity of New Drugs: A Simulation , 1986 .

[12]  L. Telser,et al.  The Theory of Supply with Applications to the Ethical Pharmaceutical Industry , 1975, The Journal of Law and Economics.

[13]  F. Tapon,et al.  Some empirical evidence on post-patent barriers to entry in the Canadian pharmaceutical industry. , 1985, Journal of health economics.

[14]  Joseph Shaanan,et al.  Stochastic-Dynamic Limiting Pricing: An Empirical Test , 1982 .

[15]  C. Fornell,et al.  Sources of Market Pioneer Advantages in Consumer Goods Industries , 1985 .

[16]  M. Stolar National survey of hospital pharmaceutical services--1982. , 1983, American journal of hospital pharmacy.

[17]  R. Schmalensee Product Differentiation Advantages of Pioneering Brands , 1980 .

[18]  W. Reekie Price and Quality Competition in the United States Drug Industry , 1978 .

[19]  D. Clarke Econometric Measurement of the Duration of Advertising Effect on Sales , 1976 .

[20]  H. Grabowski,et al.  Substitution laws and innovation in the pharmaceutical industry. , 1979 .

[21]  M. Statman,et al.  The effect of patent expiration on the market position of drugs , 1981 .

[22]  H. Grabowski,et al.  Longer Patents for Lower Imitation Barriers: The 1984 Drug Act , 1986 .

[23]  R. Dorfman,et al.  Optimal Advertising and Optimal Quality , 1976 .